Perkembangan Terkini Terapi Sistemik Psoriasis

Natalia Rania Sutanto; Windy Keumala Budianti

doi:10.36452/jkdoktmeditek.v27i2.2043

Authors

Natalia Rania Sutanto Departemen Dermatologi dan Venereologi, Fakultas Kedokteran, Universitas Indonesia/RSUPN dr. Cipto Mangunkusumo, Jakarta, Indonesia
Windy Keumala Budianti Departemen Dermatologi dan Venereologi, Fakultas Kedokteran, Universitas Indonesia/RSUPN dr. Cipto Mangunkusumo, Jakarta, Indonesia

DOI:

https://doi.org/10.36452/jkdoktmeditek.v27i2.2043

Keywords:

biosimilar, obat biologik, psoriasis, small molecules, terapi sistemik

Abstract

Psoriasis merupakan penyakit inflamasi kulit akibat aktivasi terhadap sistem imun bawaan dan adaptif. Etiopatogenesis psoriasis merupakan proses kompleks dan multifaktorial, yang dipengaruhi oleh faktor genetik dan lingkungan seperti stres, trauma, dan infeksi. Pada pasien dengan psoriasis kategori sedang hingga berat dan lesi lokalisata di area skalp, wajah, kuku, telapak tangan dan kaki, serta genital merupakan indikasi untuk pemberian terapi dengan obat sistemik. Saat ini terdapat berbagai pilihan terapi sistemik yang tersedia yaitu obat sistemik konvensional, terapi small molecules, obat biologik, dan biosimilarnya yang terdiri atas inhibitor TNF-α, inhibitor IL-12/23, inhibitor IL-17, dan inhibitor IL-23. Selama dekade terakhir, tata laksana psoriasis telah mengalami pergeseran paradigma yaitu obat biologik dan biosimilarnya mulai menjadi pilihan utama karena telah terbukti memiliki efikasi yang lebih kuat dengan efek samping minimal. Tinjauan pustaka ini membahas perkembangan terapi sistemik psoriasis terkini sehingga diharapkan dapat memberikan acuan untuk memilih terapi yang tepat, efektif, dan aman untuk pasien psoriasis.

References

Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA. 2020;323:1945-60.

Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018;54:102-13.

Cheungpasitporn W, Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. Plos One. 2019;14:1-31.

Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. J Dermatolog Treat. 2017;28:488-91.

Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20:1-28.

Gudjonsson JE, Elder JT. Psoriasis. In: Kang S AM, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, dkk, editor. Fitzpatrick’s dermatology. 9 ed. New York: McGraw Hill Education; 2019. p. 457-97.

Sasson SC, Gordon CL, Christo SN, Klenerman P, Mackay LK. Local heroes or villains: tissue-resident memory T cells in human health and disease. Cell Mol Immunol. 2020;17:113-22.

Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke WH, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1616-26.

Xu QN, Zhu HQ. The roles of skin resident memory T cells in dermatoses. Int J Dermatol Venerol. 2019;2:29-32.

Khalil S, Bardawil T, Kurban M, Abbas O. Tissue-resident memory T cells in the skin. Inflamm Res. 2020;69:245-54.

Novianto E, Fitri EM, Budianti WK, penyunting. Alur tata laksana psoriasis vulgaris (tipe plak) di Indonesia. 1 ed. Jakarta: Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia; 2019. 1-22 p.

Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, et al. Joint American academy of dermatology-national psoriasis foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82:1445-86.

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1:1-604.

Ronholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18:1-23.

Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37-49.

Tegtmeyer K, Zhao J, Maloney NJ, Atassi G, Beestrum M, Lio PA. Off-label studies on tofacitinib in dermatology: a review. J Dermatolog Treat. 2019;1:1-11.

Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173:949-61.

Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14:719-30.

Arnone M, Takahashi MDF, Carvalho AVEd, Bernardo WM, Bressan AL, Ramos AMC, et al. Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian society of dermatology. Anais Brasileiros de Dermatologia. 2019;94:76-107.

Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British association of dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183:628-37.

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.

Bissonnette R, Luger T, Thaci D, Toth D, Lacombe A, Xia S, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32:1507-14.

Neema S, Singh S, Pathak N, Khan MA. Widespread superficial dermatophytosis in patient on secukinumab for treatment of chronic plaque psoriasis. Indian Dermatol Online J. 2019;10:76-8.

Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res. 2019;2019:1-25.

Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, et al. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2018;62:46-58.

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318-28.

Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81:44-52.

Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418-31.

Nemoto O, Hirose K, Shibata S, Li K, Kubo H. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study. B J Dermatol. 2018;178:689-96.

Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178:114-23.

Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. The Lancet. 2017;390:276-88.

Li W, Ghamrawi R, Haidari W, Feldman SR. Risankizumab for the treatment of moderate to severe plaque psoriasis. Ann Pharmacother. 2020;54:380-87.

McKeage K, Duggan S. Risankizumab: first global approval. Drugs. 2019;79:893-900.

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156:258-69.

Kellen R, Goldenberg G. Biosimilars in psoriasis: the future or not? Cutis. 2017;99:116-20.

Feagan BG, Lam G, Ma C, Lichtenstein GR. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2019;49:31-40.

Cohen AD, Wu JJ, Puig L, Chimenti S, Vender R, Rajagopalan M, et al. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol. 2017;177:1495-502.

National Psoriasis Foundation. Biologic & biosimilars for psoriasis. [Internet]. 2020. [cited 2020 Oct 30]. Available from: https://www.psoriasis.org/biologics/.

Puig L, Lopez-Ferrer A. Biosimilars for the treatment of psoriasis. Expert Opin Biol Ther. 2019;19:993-1000.

Moots RJ, Curiale C, Petersel D, Rolland C, Jones H, Mysler E. Efficacy and safety outcomes for originator TNF inhibitors and biosimilars in rheumatoid arthritis and psoriasis trials: a systematic literature review. BioDrugs. 2018;32:193-9.

Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76:1093-102.